Vincristine‐induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia

Tay, Chee Geap; Lee, Vanessa Wan Mun; Ong, Lai Choo; Goh, Khean Jin; Ariffin, Hany; Fong, Choong Yi

doi:10.1002/pbc.26471

Cited by 92 publications

(80 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, we observed that impaired quadriceps strength, impaired cardiopulmonary fitness, decreased balance, and impaired peripheral nervous system integrity were associated with lower scores on the SF‐36 summary scales. This finding is concordant with previous reports among childhood cancer survivors where it was shown that self‐reported function and/or symptoms influence HRQoL, and similar to studies in other cancer survivor populations (adult and pediatric) where it was shown that reduced aerobic capacity, muscular weakness, inadequate postural control, and neuropathy influence perceived health. To our knowledge, this is the first study that has evaluated a link between fitness, peripheral nervous system integrity, and HRQoL among survivors of childhood HL.…”

Section: Discussionsupporting

confidence: 92%

Physical fitness in survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort

Wogksch

Howell

Wilson

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background There are limited data describing fitness and associated health‐related quality of life (HRQoL) in survivors of childhood Hodgkin lymphoma (HL). Procedure Fitness was evaluated among 336 adult survivors of childhood‐onset HL treated at St. Jude Children's Research Hospital and 327 controls who never had childhood cancer. The controls were frequency matched on age, sex, and race. Associations were examined between chronic disease and fitness and between fitness and HRQoL using a multivariable linear and logistic regression. Results Male survivors had lower endurance (6‐min walk [6MW] distance 604.4 ± 7.9 m vs 637.0 ± 7.5 m, P < 0.01), and worse neuropathy (modified Total Neuropathy Score [mTNS] 2.7 ± 0.2 vs 1.4 ± 0.2, P < 0.01) compared to controls. Female survivors had lower endurance (6MW distance 564.5 ± 6.9 m vs 590.6 ± 7.0 m, P < 0.01), quadriceps strength (145.7 ± 4.0 vs 163.4 ± 4.0 N·m per kilogram, P < 0.01), and worse neuropathy (mTNS 3.2 ± 0.2 vs 1.4 ± 0.3, P < 0.01) compared to controls. Moderate, severe/disabling, or life‐threatening (grades 2‐4) neurological conditions were associated with impaired quadriceps strength (odds ratio [OR] 2.94, 99% confidence interval [CI] 1.24‐6.96) and impaired endurance (OR 2.96, 99% CI 1.28‐6.69). Cardiovascular (OR 2.36, 99% CI 1.00‐5.61) and pulmonary (OR 2.78, 99% CI 1.30‐5.94) conditions were associated with impaired endurance. Quadriceps strength (β –6.44 ± 2.01, P < 0.01), endurance (β –4.63 ± 1.54, P < 0.01), and neuropathy (β –4.98 ± 1.14, P < 0.01) were associated with a lower physical component summary on the HRQoL. Conclusion Survivors of childhood HL, particularly those with neurological, cardiac, and pulmonary chronic conditions, are at risk for impaired fitness and HRQoL.

show abstract

Section: Discussionsupporting

confidence: 92%

Physical fitness in survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort

Wogksch

Howell

Wilson

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…While the reported incidence rates vary considerably—depending on the severity of symptoms, diagnostic criteria and concomitant use of other neurotoxic agents—most patients receiving vincristine develop some degree of sensory peripheral neuropathy at a cumulative dose of >4 mg/m 2 (Ramchandren et al, 2009; Toopchizadeh et al, 2009; Seretny et al, 2014; Lavoie Smith et al, 2015; Tay et al, 2017). …”

Section: Cancer Chemotherapy: Drug Mechanism Of Action and Metabolitesmentioning

confidence: 99%

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

Starobova

Vetter

2017

Front. Mol. Neurosci.

472

400

View full text Add to dashboard Cite

Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment, and severely affects the quality of life of cancer survivors. Clinically, chemotherapy-induced peripheral neuropathy presents as deficits in sensory, motor, and autonomic function which develop in a glove and stocking distribution due to preferential effects on longer axons. The pathophysiological processes are multi-factorial and involve oxidative stress, apoptotic mechanisms, altered calcium homeostasis, axon degeneration and membrane remodeling as well as immune processes and neuroinflammation. This review focusses on the commonly used antineoplastic substances oxaliplatin, cisplatin, vincristine, docetaxel, and paclitaxel which interfere with the cancer cell cycle—leading to cell death and tumor degradation—and cause severe acute and chronic peripheral neuropathies. We discuss drug mechanism of action and pharmacokinetic disposition relevant to the development of peripheral neuropathy, the epidemiology and clinical presentation of chemotherapy-induced neuropathy, emerging insight into genetic susceptibilities as well as current understanding of the pathophysiology and treatment approaches.

show abstract

“…Vincristine is administered in weekly intervals with a dose of 1.5 to 2 mg/m . Among the vinca alkaloids, vincristine is the most neurotoxic and patients receiving vincristine develop some degree of vincristine‐induced peripheral neuropathy (VIPN) at a cumulative dose of >4 mg/m 2 . However, recently marketed lipid‐coated or liposomal vincristine increased the safety margin and tissue penetration .…”

Section: Oncological Use Dose and Neurotoxicitymentioning

confidence: 99%

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

Islam

Lustberg

Staff

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Vinca alkaloids, thalidomide, and eribulin are widely used to treat patients with childhood acute lymphoblastic leukemia (ALL), adults affected by multiple myeloma and locally invasive or metastatic breast cancer, respectively. However, soon after their introduction into clinical practice, chemotherapy-induced peripheral neurotoxicity (CIPN) emerged as their main non-hematological and among dose-limiting adverse events. It is generally perceived that vinca alkaloids and the antiangiogenic agent thalidomide are more neurotoxic, compared to eribulin. The exposure to these chemotherapeutic agents is associated with an axonal, length-dependent, sensory polyneuropathy of mild to moderate severity, whereas it is considered that the peripheral nerve damage, unless severe, usually resolves soon after treatment discontinuation. Advanced age, high initial and prolonged dosing, coadministration of other neurotoxic chemotherapeutic agents and pre-existing neuropathy are the common risk factors. Pharmacogenetic biomarkers might be used to define patients at increased susceptibility of CIPN. Currently, there is no established therapy for CIPN prevention or treatment; symptomatic treatment for neuropathic pain and dose reduction or withdrawal in severe cases is considered, at the cost of reduced cancer therapeutic efficacy. This review critically examines the pathogenesis, epidemiology, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of CIPN as a result of exposure to vinca alkaloids, thalidomide and its analogue lenalidomide as also eribulin. K E Y W O R D S assessment, eribulin, peripheral neurotoxicity, thalidomide, vinca alkaloids

show abstract

Vincristine‐induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia

Abstract: Sixteen percent of ALL survivors had VIPN. VIPN should be increasingly recognised as a late effect of chemotherapy, as it significantly affects physical and social function quality of life.

Cited by 92 publications

References 38 publications

Physical fitness in survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort

Physical fitness in survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

Contact Info

Product

Resources

About